跳至主要内容
临床试验/NCT00139438
NCT00139438已完成不适用

Improving Management of Patients at High Risk for Osteoporotic Fractures

Merck Sharp & Dohme LLC0 个研究点目标入组 4,266 人开始时间: 2004年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
4,266
主要终点
A composite measure of bone mineral density (BMD) testing and/or osteoporosis medications prescriptions.

研究概览

简要总结

The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test and percent appropriately prescribed a medication for osteoporosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Members of the Horizon Blue Cross Blue Shield of New Jersey who are at risk for osteoporosis based on age (women age 65 or older, men and women age 45 or older who have a history of fragility fracture or have a history of taking oral glucocorticoids over 3 months).

排除标准

  • Individuals who are not members of Horizon Blue Cross Blue Shield of New Jersey and who otherwise do not meet the inclusion criteria.

结局指标

主要结局

A composite measure of bone mineral density (BMD) testing and/or osteoporosis medications prescriptions.

次要结局

  • BMD testing, osteoporosis medication prescriptions, fracture

研究者

申办方类型
Industry
责任方
Sponsor

相似试验